Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study reveals structure of tuberculosis enzyme, could offer drug target

03.11.2015

A team of scientists, including several from the U.S. Department of Energy's Argonne National Laboratory, have determined the structures of several important tuberculosis enzymes, which could lead to new drugs for the disease.

Tuberculosis, caused by Mycobacterium tuberculosis bacteria, has proved incredibly stubborn even in the age of powerful antibiotics, infecting about one third of all people worldwide. Treatment can take up to nine months. It has stealth properties that protect it from antibiotics; it can hide inside human cells, avoiding the body's immune system while it waits for the opportune moment to multiply; and it's very resourceful at acquiring resistance.


Scientists determined the structures of several important tuberculosis enzymes, which could lead to new drugs for the disease. Above: An image of the mycobacterium IMPDH complex when it is attached to IMP and the inhibitor MAD1.

Courtesy Youngchang Kim/Argonne National Laboratory.

"What we have now may not work in a few years," said Andrzej Joachimiak, an Argonne Distinguished Fellow, head of the Structural Biology Center, co-principal investigator at the Center for Structural Genomics of Infectious Diseases and a corresponding author on the new study.

In order to make new drugs, researchers need to search through the thousands of proteins in the bacterial world to find one that does something so important the bacterium can't live without it--and then make a little block to match.

One such entry point might be IMPDH (inosine-5?-monophosphate dehydrogenase), which is part of a cellular process that controls the making of guanine nucleotides, one of the building blocks for DNA and RNA. It's so essential that virtually all living organisms, including human and bacterial pathogens, have versions of it.

"What we discovered earlier this year is that the human and bacterial versions bind molecules differently," Joachimiak said. "This is very important for finding a molecule to build a drug around--you don't want to inhibit a human enzyme, just the pathogen one."

Researchers have been interested in the mycobacterium IMPDH enzyme as a drug target for years, Joachimiak said, but haven't been able to produce it well enough to study it.

The team observed that one part of the enzyme's structure was particularly wobbly, so they engineered a version without it using resources at the Advanced Protein Characterization Facility and then then determined the structure employing synchrotron protein crystallography at the Advanced Photon Source, a DOE Office of Science User Facility (both at Argonne).

The modified version functions very similarly to the original, Joachimiak said, but is much easier to purify and crystallize for study.

Brandeis University professor Lizbeth Hedstrom and University of Minnesota professor Courtney Aldrich, two of the study's other research collaborators, had identified several inhibitor molecules that bind to IMPDH, and thus might be a starting point for a drug--but they couldn't be imaged while interacting with the enzyme. The new engineered enzyme allowed them to capture the structures of Hedstrom's and Aldrich's inhibitors in action, locked with IMPDH.

Helena Boshoff at the National Institute of Allergies and Infectious Diseases performed complementary studies showing that these inhibitors do in fact efficiently block mycobacterium growth.

The new structures were deposited into the Protein Data Bank for continued study.

###

The study, "Mycobacterium tuberculosis IMPDH in Complexes with Substrates, Products and Antitubercular Compounds," was led by Magdalena Makowska-Grzyska with the University of Chicago's Center for Structural Genomics of Infectious Diseases (CSGID); Argonne and CSGID protein crystallographer Youngchang Kim also co-authored the study. Other collaborators included researchers with Brandeis University, the National Institute of Allergies and Infectious Diseases (NIAID), the University of Minnesota, and the University of Houston. The research was supported by the National Institutes of Health and NIAID. Use of the Structural Biology Center was supported by the DOE Office of Science.

Argonne National Laboratory seeks solutions to pressing national problems in science and technology. The nation's first national laboratory, Argonne conducts leading-edge basic and applied scientific research in virtually every scientific discipline. Argonne researchers work closely with researchers from hundreds of companies, universities, and federal, state and municipal agencies to help them solve their specific problems, advance America's scientific leadership and prepare the nation for a better future. With employees from more than 60 nations, Argonne is managed by UChicago Argonne, LLC for the U.S. Department of Energy's Office of Science.

The U.S. Department of Energy's Office of Science is the single largest supporter of basic research in the physical sciences in the United States and is working to address some of the most pressing challenges of our time. For more information, visit the Office of Science website.

Media Contact

Brian Grabowski
bgrabowski@anl.gov
630-252-1232

 @argonne

http://www.anl.gov 

Brian Grabowski | EurekAlert!

More articles from Life Sciences:

nachricht NYSCF researchers develop novel bioengineering technique for personalized bone grafts
18.07.2018 | New York Stem Cell Foundation

nachricht Pollen taxi for bacteria
18.07.2018 | Technische Universität München

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First evidence on the source of extragalactic particles

For the first time ever, scientists have determined the cosmic origin of highest-energy neutrinos. A research group led by IceCube scientist Elisa Resconi, spokesperson of the Collaborative Research Center SFB1258 at the Technical University of Munich (TUM), provides an important piece of evidence that the particles detected by the IceCube neutrino telescope at the South Pole originate from a galaxy four billion light-years away from Earth.

To rule out other origins with certainty, the team led by neutrino physicist Elisa Resconi from the Technical University of Munich and multi-wavelength...

Im Focus: Magnetic vortices: Two independent magnetic skyrmion phases discovered in a single material

For the first time a team of researchers have discovered two different phases of magnetic skyrmions in a single material. Physicists of the Technical Universities of Munich and Dresden and the University of Cologne can now better study and understand the properties of these magnetic structures, which are important for both basic research and applications.

Whirlpools are an everyday experience in a bath tub: When the water is drained a circular vortex is formed. Typically, such whirls are rather stable. Similar...

Im Focus: Breaking the bond: To take part or not?

Physicists working with Roland Wester at the University of Innsbruck have investigated if and how chemical reactions can be influenced by targeted vibrational excitation of the reactants. They were able to demonstrate that excitation with a laser beam does not affect the efficiency of a chemical exchange reaction and that the excited molecular group acts only as a spectator in the reaction.

A frequently used reaction in organic chemistry is nucleophilic substitution. It plays, for example, an important role in in the synthesis of new chemical...

Im Focus: New 2D Spectroscopy Methods

Optical spectroscopy allows investigating the energy structure and dynamic properties of complex quantum systems. Researchers from the University of Würzburg present two new approaches of coherent two-dimensional spectroscopy.

"Put an excitation into the system and observe how it evolves." According to physicist Professor Tobias Brixner, this is the credo of optical spectroscopy....

Im Focus: Chemical reactions in the light of ultrashort X-ray pulses from free-electron lasers

Ultra-short, high-intensity X-ray flashes open the door to the foundations of chemical reactions. Free-electron lasers generate these kinds of pulses, but there is a catch: the pulses vary in duration and energy. An international research team has now presented a solution: Using a ring of 16 detectors and a circularly polarized laser beam, they can determine both factors with attosecond accuracy.

Free-electron lasers (FELs) generate extremely short and intense X-ray flashes. Researchers can use these flashes to resolve structures with diameters on the...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Leading experts in Diabetes, Metabolism and Biomedical Engineering discuss Precision Medicine

13.07.2018 | Event News

Conference on Laser Polishing – LaP: Fine Tuning for Surfaces

12.07.2018 | Event News

11th European Wood-based Panel Symposium 2018: Meeting point for the wood-based materials industry

03.07.2018 | Event News

 
Latest News

NYSCF researchers develop novel bioengineering technique for personalized bone grafts

18.07.2018 | Life Sciences

Machine-learning predicted a superhard and high-energy-density tungsten nitride

18.07.2018 | Materials Sciences

Why might reading make myopic?

18.07.2018 | Health and Medicine

VideoLinks
Science & Research
Overview of more VideoLinks >>>